Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)

Circulation

Volumn 136, Issue 4, 2017, Pages 359-366

  Braamskamp, Marjet J A M ^a   Langslet, Gisle ^b   Mccrindle, Brian W ^c   Cassiman, David ^d   Francis, Gordon A ^e,f   Gagne, Claude ^g   Gaudet, Daniel ^h   Morrison, Katherine M ⁱ   Wiegman, Albert ^a   Turner, Traci ^j   Miller, Elinor ^k   Kusters, D Meeike ^a   Raichlen, Joel S ^k   Martin, Paul D ^k   Stein, Evan A ^j   Kastelein, John J P ^a   Hutten, Barbara A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e ST PAUL S HOSPITAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Clinique des Maladies Lipidiques de Québec Inc   (Canada)

^h UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j Metabolic and Atherosclerosis Research Center   (United States)

^k ASTRAZENECA   (United Kingdom)

more..

Author keywords

carotid intima media thickness; child; cholesterol, LDL; hypercholesterolemia, familial; rosuvastatin calcium

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ADOLESCENT; ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; CAROTID BULB; CHILD; COMMON CAROTID ARTERY; DEMOGRAPHY; DRUG DOSE TITRATION; DRUG EFFECT; ECHOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY RELATION; FEMALE; FOLLOW UP; GENDER; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INTERNAL CAROTID ARTERY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; YOUNG ADULT; CLINICAL TRIAL; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; MULTICENTER STUDY; TREATMENT OUTCOME; TRENDS;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; CAROTID INTIMA-MEDIA THICKNESS; CHILD; FEMALE; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME;

EID: 85021148464     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.025158     Document Type: Article

References (20)

1. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34: 3478-3490. doi: 10.1093/eurheartj/eht273.
2. Goldstein JL, Hobbs HH, Brown MS. Part 12: Lipids: chapter 120: Familial Hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B, Childs B, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill Medical; 2001: 2863-2913.
3. Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierod MB, Leren TP, Retterstol K. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010. J Am Heart Assoc. 2014; 3: e001236. doi: 10.1161/JAHA.114.001236.
4. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJ, Kastelein JJ. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004; 363: 369-370.
5. de Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJ, Stroes ES. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis. 2002; 163: 193-197.
6. Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res. 2014; 114: 307-310. doi: 10.1161/CIRCRESAHA.114.301430.
7. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjærg-Hansen A, Wiklund O; European Ath erosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015; 36: 2425-2437. doi: 10.1093/eurheartj/ehv157.
8. Expert Panel on Integrated Guidelines for Cardiovascular Health, Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128(suppl 5): S213-S256. doi: 10.1542/peds.2009-2107C.
9. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA. A systematic review and meta-Analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007; 27: 1803-1810. doi: 10.1161/ATVBAHA.107.145151.
10. Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010; 55: 1121-1126. doi: 10.1016/j.jacc.2009.10.042.
11. Braamskamp MJ, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, Gaudet D, Morrison KM, Wiegman A, Turner T, Kusters DM, Miller E, Raichlen JS, Wissmar J, Martin PD, Stein EA, Kastelein JJ. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study. J Clin Lipidol. 2015; 9: 741-750. doi: 10.1016/j.jacl.2015.07.011.
12. Kusters DM, Hutten BA, McCrindle BW, Cassiman D, Francis GA, Gagné C, Gaudet D, Morrison KM, Langslet G, Kastelein JJ, Wiegman A. Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. J Clin Lipidol. 2013; 7: 408-413. doi: 10.1016/j.jacl.2013.06.010.
13. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007; 115: 1948-1967. doi: 10.1161/CIRCULATIONAHA.107.181946.
14. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989; 9: 105-135.
15. Bots ML. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin. 2006; 22: 2181-2190. doi: 10.1185/030079906X148472.
16. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O?Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007; 297: 1344-1353. doi: 10.1001/jama.297.12.1344.
17. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004; 292: 331-337. doi: 10.1001/jama.292.3.331.
18. Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegman A, Hutten BA. Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA. 2014; 312: 1055-1057. doi: 10.1001/jama.2014.8892.
19. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all-cause, cancer, and coronary mortality in statin-Treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008; 29: 2625-2633. doi: 10.1093/eurheartj/ehn422.
20. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008; 337: a2423. doi: 10.1136/bmj.a2423.